Mednet Logo

Would you offer definitive chemoRT for NSCLC with histologically-proven contralateral station 11 nodal involvement?

If so, how would you approach managing the increase in lung dose required to cover these? Would you consider this metastatic disease?
3 Answers
Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Cleveland Clinic
Answered on

Contralateral hilar involvement is staged as N3 per AJCC 8th edition. In that regard, the management of an N3 patient should mimic that which we consider for any locally advanced IIIB or IIIC patient. Full staging including brain MRI is necessary. Pulmonary function testing including spirometry and ...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · UCLA | VA Greater Los Angeles Healthcare System
Answered on

Most importantly, get a biopsy to confirm the contralateral LN is real. If positive, these patients need both drugs and radiotherapy to have an optimal chance at long-term survival. Local control remains a problem which is why concurrent is favored over sequential. If safe, CRT can be optimized by d...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Radiation Oncology · University of Alabama at Birmingham
Answered on · Updated on

Yes. Can cover PTV 95% at 95%, motion management (eg: phase gating), precise contours/expansions (crop CTV out of anatomy that is not at risk), and image guidance to minimize PTV expansion. Adaptive treatment (shrinking target volume as tumor responds) is not standard yet but is used occasionally at...

Join for free or sign in to see the full answer